Junsik Park

Assistant Professor

Soonchunhyang University Hospital Bucheon

South Korea

Research Interests

Explore related searches

Professors in South Korea Professors in Immunology Immunology professors in South Korea

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Junsik Park is an Assistant Professor at Soonchunhyang University Bucheon Hospital, South Korea. His research focuses on immunotherapy, particularly in the context of glioblastoma and ovarian cancer, with recent articles examining the interactions of immune checkpoint inhibitors and treatment responses in various malignancies. Dr. Park's work includes novel therapeutic strategies to enhance anti-tumor immunity and the use of deep learning techniques for treatment prediction.

Articles (15)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

SOUTH KOREA

View details

Associate Professor

Yonsei University

SOUTH KOREA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Junsik Park

Research Interests

Explore related searches

Contact this professor

About

Articles (15)

Co-blockade of TGFβ and PD-1 Reinvigorates Glioblastoma-Infiltrating CD8+ T Cells That Characteristically Upregulate TGFβRI Expression

Neoadjuvant Chemotherapy with Dual Immune Checkpoint Inhibitors for Advanced-Stage Ovarian Cancer: Final Analysis of TRU-D Phase II Nonrandomized Clinical Trial

Novel anti-CD73-IL-2v bispecific fusion protein augments antitumor immunity by alleviating immunosuppressive adenosine pathways in CD8 + T cells

Histopathologic image–based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer

Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8+TILs based onBRCA1/2mutation status in epithelial ovarian cancers

Anti–4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade

OPERA: a phase II trial of oregovomab plus non-platinum chemotherapy in PARP inhibitor/platinum-resistant ovarian cancer

Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial

CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy

Frequency of peripheral PD-1+regulatory T cells is associated with treatment responses to PARP inhibitor maintenance in patients with epithelial ovarian cancer

Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D

Comprehensive genomic and immunohistochemical profiles and outcomes of immunotherapy in patients with recurrent or advanced cervical cancer

Dynamics of the Tumor Immune Microenvironment during Neoadjuvant Chemotherapy of High-Grade Serous Ovarian Cancer

A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial

Comparison of the Prognostic Outcome between High-Grade Ovarian Sertoli-Leydig Cell Tumors (SLCTs) and Low-Grade SLCTs

Collaborators (11)

Je-Gun Joung

Seok-Gu Kang

Yong-Moon Lee

Jae-Weon Kim

Kyung Jin Eoh

Sang Wun Kim

Su-Hyung Park

Yong Jae Lee

Jae Kwan LEE

Jung Bok Lee

Jung-Yun Lee

Make your next move.